This guidance is being distributed to all treating physicians worldwide except those in the European Union (EU). Separate guidance will be sent to European healthcare professionals in accordance with the requirements of the European Medicines Agency (EMEA); we expect that document to be distributed on or before 16th January 2009 and we would hope to publish it on this website soon afterwards.
Please Click Here to read the Myozyme Stakeholders Working Group Guidance Document (PDF, 39 kB)